Introduction to computational and systems biology

Lecture 10: Network Controllability analysis

Ion Petre

Department of Mathematics and Statistics University of Turku Fall 2019

What is network controllability?



The ability to change the *global behaviour* of a complex network through well-chosen *minimal local interventions*, taking advantage of the internal inter-connections in the network

Liu, Slotine, Barabasi (2011)



Controllability of linear networks

- **Concept:** A linear dynamical system is *controllable* (from a given set of input nodes) if it can be "driven" from any initial state to any desired final state in finite time
- **Example:** drive a cancer cell to an apoptotic state



Two questions

• Question 1: Is the system (A,B) controllable?

•In other words, can we find for any initial state I and final state F, a suitable input u(t) that drives the system from I to F in finite time?

$$\frac{dx(t)}{dt} = Ax(t) + Bu(t)$$

• Question 2: For a system A, what is the "smallest" input B such that (A,B) is controllable



An elegant solution to Q1

- Kalman (1963): a linear model is controllable iff its controllability matrix has full rank
 - Controllability matrix: [B | AB | A²B | ... | Aⁿ⁻¹B]
 - Note: switch from ODEs to linear algebra

•Limitation: all kinetic details are assumed to be known; difficult for a large model



Structural controllability: elegant results for Q1 & Q2

- **Definition:** A linear model (A,B) is *structurally controllable* if there exists a suitable numeric assignment for the non-zero values of A and B such that (A',B') becomes controllable.
 - Key advantages:
 - Focus on the structure, not on the detailed kinetic setup
 - Switch from *linear algebra* to graph theory
 - Result (Lin 1974, Shields and Pearson 1976): if a network is structurally controllable, then it is controllable in all, except a thin set of kinetic setups



- Result (Liu et al 2011): Elegant and efficient algorithmic solution to find the **minimum** set of driver nodes needed to control the full network.
 - Key insight: the problem is about special paths in a directed graph

Liu, Slotine and Barabasi (2011)

Туре	Name	N	L	$n_{\rm D}^{\rm real}$
Regulatory	TRN-Yeast-1	4,441	12,873	0.965
	TRN-Yeast-2	688	1,079	0.821
	TRN-EC-1	1,550	3,340	0.891
	TRN-EC-2	418	519	0.751
	Ownership-USCorp	7,253	6,726	0.820
Trust	College student	32	96	0.188
	Prison inmate	67	182	0.134
	Slashdot	82,168	948,464	0.045
	WikiVote	7,115	103,689	0.666
	Epinions	75,888	508,837	0.549
Food web	Ythan	135	601	0.511
	Little Rock	183	2,494	0.541
	Grassland	88	137	0.523
	Seagrass	49	226	0.265
Power grid	Texas	4,889	5,855	0.325
Metabolic	Escherichia coli	2,275	5,763	0.382
	Saccharomyces cerevisiae	1,511	3,833	0.329
	Caenorhabditis elegans	1,173	2,864	0.302
9 Electronic circuits	\$838	512	819	0.232
2.00010110 010410			010	0.202

Table 1 | The characteristics of the real networks analysed in the paper

Target controllability



The ability to change the behaviour of a *target subset*

Target controllability

- Linear dynamical systems with output
 - $\frac{dx(t)}{dt} = Ax(t) + Bu(t)$
 - y(t) = Cx(t), where C is the output matrix
 - Our focus: $C_{t,t}=1$ for all nodes t in the target set T, and it is 0 otherwise. Also denoted as $C=C_T$
- *Structural target controllability*: the possibility to turn the system controllable by modifying the non-zero values in A, B, C
 - Result (Lin 1974, Shields and Pearson 1976): if a network is structurally target controllable, then it is target controllable in all, except a thin set of kinetic setups

Graph-based target controllability

- Insight: *linear dynamical systems can be represented as directed weighted graphs*
 - $\frac{dx(t)}{dt} = Ax(t) + Bu(t)$
 - $y(t) = C_T x(t)$



Graph-based structural target controllability

- Key result for Q1':
 - (Poljak, Murota 1990) If (A,B,C_T), with |T|=k, is *structurally target controllable*, then
 - there is a set of k paths starting in the driver nodes and ending in each of the target nodes such that
 - no two paths intersect at the same distance from their end points



Q2': Can a target be controlled?

• Input:

- The internal nodes and their interconnections
- The target nodes
- Output:
 - A (minimal?) set of driver nodes such as the linear system is structurally target controllable
- Goal (based on Poljak, Murota 1990): choose a set of driver nodes so that
 - there are k paths starting in the driver nodes and ending in each of the target nodes
 - no two paths intersect at the same distance from their end points





Can a target be controlled?

- Goal (based on Poljak, Murota 1990) : choose a set of driver nodes so that
 - there are k paths starting in the driver nodes and ending in each of the target nodes
 - no two paths intersect at the same distance from their end points
- Key insight: this is an iterated matching problem
 - Match the targets to some internal nodes; they become the new targets
 - Match the new targets against the internal nodes;
 - Those remaining unmatched become driver nodes
 - The left side of the matching becomes the new target
 - Stop the iteration after n steps and make all remaining targets driver nodes



Gao et al. – Target controllability: a greedy-type approximation (2014)



ARTICLE

Received 20 Feb 2014 | Accepted 30 Sep 2014 | Published 12 Nov 2014

DOI: 10.1038/ncomms6415

Target control of complex networks

Jianxi Gao¹, Yang-Yu Liu^{1,2,3}, Raissa M. D'Souza^{4,5} & Albert-László Barabási^{1,2,3}

Controlling large natural and technological networks is an outstanding challenge. It is typically neither feasible nor necessary to control the entire network, prompting us to explore target control: the efficient control of a preselected subset of nodes. We show that the structural

Target Controllability

• Our results:

- The Target Controllability optimisation problem is NP-hard
- Fastest heuristics algorithms and better approximation results
- Control algorithms which **maximize the use of FDA-approved drugs** in controlling essential genes
- An automated (Web-based) software for bio-net control
- Demonstrated the approach for several types of cancer
- Controlling Directed Protein Interaction Networks in Cancer. *Scientific Reports* 2017. **Top 5% most read oncology papers in Scientific Reports 2017.**
- Structural target controlability of linear networks. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, 2018.
- Controlability of Linear Networks. **nVidia Best Paper Award CMSB 2016.**
- NetContrl4BioMed: A pipeline for biomedical data acquisition and analysis of network controllability. *BMC Bioinformatics* 2018.

Target controllability in the biomedical domain

- Input controller is implemented through drugs
- Staying realistic
 - No super-drugs: input nodes have bounded out-degree
 - Matrix B has at most N non-zero values on every column
 - **Minimize the number of drugs** given to a patient: minimize the number of input (also called driver) nodes
 - **FDA-approved drugs**: the list of potential driven nodes may be given in the input of the problem

Target controllability as an optimization problem

- Target-control optimization problem
- Input: Matrix A (n x n) and matrix C (k x n), with k≤n, where every row and column of C have at most one non-zero entry with value 1.
- **Output**: Matrix B (n x m) such that
 - Srank (CB | CAB | CA²B |... | CAⁿ⁻¹B)=k
 - m is minimum
 - Result: the (decision) problem is NP-hard!

- Target Control Optimization Problem (TCP)
- Input: Matrix A (n x n) and matrix C (k x n), with k≤n, where every row and column of C have at most one non-zero entry with value 1.
- **Output**: Matrix B (n x m) such that
 - Srank (CB | CAB | CA²B | ... | CAⁿ⁻¹B)=k
 - m is minimum
- N-bounded Target Control Optimization Problem (N-TCP)
- Additional condition for the output: B contains at most N non-zero values on every column
- Edge-bounded Target Control Optimization Problem (E-TCP)
- Alternative optimization for the output: B contains a minimum number of non-zero rows
- The decision versions of all these problems defined in the usual way:

• TCP-d N-TCP-d E-TCP-d

• Result: all of these decision problems are NP-hard!

www.nature.com/scientificreports

SCIENTIFIC REPORTS



Controlling Directed Protein Interaction Networks in Cancer

Krishna Kanhaiya¹, Eugen Czeizler^{1,2}, Cristian Gratie¹ & Ion Petre¹

Control theory is a well-established approach in network science, with applications in bio-medicine and cancer research. We build on recent results for structural controllability of directed networks, which identifies a set of driver nodes able to control an a-priori defined part of the network. We develop a novel and efficient approach for the (targeted) structural controllability of cancer networks and demonstrate it for the analysis of breast, pancreatic, and ovarian cancer. We build in each case a protein-protein interaction network and focus on the survivability-essential proteins specific to each cancer type. We show that these essential proteins are efficiently controllable from a relatively small computable set of driver nodes. Moreover, we adjust the method to find the driver nodes among FDA-approved drug-target nodes. We find that, while many of the drugs acting on the driver nodes are part of known cancer therapies, some of them are not used for the cancer types analyzed here; some drug-target driver nodes identified by our algorithms are not known to be used in any cancer therapy. Overall we show that a better understanding of the control dynamics of cancer through computational modelling can pave the way for new efficient therapeutic approaches and personalized medicine.

Target control of cancer essential genes

- Consider three types of cancer:
 - Breast cancer,
 - Pancreatic cancer,
 - Ovarian cancer.
- Select the relevant set of cancer-specific genes/proteins
- Select a set of (target) essential genes
- Use known gene signalling/regulatory/interaction networks to derive the cancer-specific gene interaction network

Essential genes, Drug targets, and Signaling networks



Literature-based validation

Drug-target	Target genes	Anti-cancer drug	Know to be used in cancer therapies
ERBB2	CDK1, CDCH2, CDC7, SH3RF1, APLP2	Lapatinib	Breast, Lung
SRC	PLK1, RAN, MAP2K1, KARS	Dasatinib, Bosutinib, Ponatinib	CML
PDPK1	PNK1, ERBB3, SH3RF1, PDPK1	None	None
PRKDC	GBF1, MN1, RPA2	None	None
MTOR	PHB2, RPTOR, MTOR	Temsirolimus	RCC, BMC
JAK2	MAP3K5, AIRE	Ruxolitinib, Erlotinib	Pancreatic
HDAC3	SP1, HDAC3	Vorinostat	CTCL
CDK2	PFN1, TFCP2	None	None

Our predictions on drug-target proteins with highest potential impact for breast cancers.

NetControl4BioMed: Network Controllability for Biomedicine



NetControl4BioMed

http://combio.org/

Kanhalya et ol. 8MC Bioinformatics 2018, 19(Suppl 7):185 https://doi.org/10.1186/s12859-018-2177-3	BMC Bioinformatics
SOFTWARE	Open Access
NetControl4BioMed: a pip biomedical data acquisition network controllability	beline for Or on and analysis of

ANALYZE

Please Enter a Valid Email Address (The pipeline will report its progress here):

List of Seed Proteins to Generate the Network 2

Custom network

Choose File no file selected

NetControl4BioMed 2020 release



waata a maxi amali ala				
reate a new analysis			← Discar	d and go
20%				
Choose the network:				
Generate a new network				
Choose the type identifier:				
Please select an option				
Choose the database:				
Please select an option				
Choose the network size:				
Please select an option				
Enter the seed nodes here:		Or, alternatively, select a	file to upload its o	content.
Write here the seed nodes.		Choose file		Brow
		The content of the uploa	aded file will appe	ear here.
	1,			
There are 0 unique nodes above.				
Previous			Next	



Example: multiple myeloma

- Jens Lohr et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell* 2014.
 - 203 patients
 - Genetic mutation data, copy number alterations
- Approach
 - Disease-specific analysis on this data set
 - Network around the most frequently mutated genes
 - Predict drug combinations
 - Validate against standard therapy lines
 - Patient-specific analysis
 - Network around the patient's own mutated genes
 - Predict drug combinations
 - Analyze differences wrt the standard therapy lines

Current research lines

- Controllability in a (semi-)quantitative framework
 - Approximations over ODEs
 - Boolean networks
 - •••

٠

- Edge-labeled directed graphs
 - Activation, inhibition influences
- More complex behavior of the driver nodes
 - Side-effects
 - Synergy effects
- Approximation guarantees for our various heuristics
- Proof of concept in personalized medicine
- Multi-clone tumors
- Clinical validation

Contributors

• E. Czeizler



V. Rogojin









C. Gratie

ACADEMY

OF FINLAND



V. Popescu



Challenge Finland

K. Chiu Wu





- Andrei Andronescu (Bucharest) ٠
- Diana Ion (Bucharest) ٠
- Eduard Mititelu (Bucharest)
- Alex Nedea (Bucharest)
- Sadra Safa (Tehran)
- Negin Majidi (Tehran) ٠
- Daniela Schacherer (Heidelberg) ٠
- Jose Angel Sanchez Martin (Madrid)
- Nicoleta Balteanu (Bucharest)
- Patric Gustafsson (Turku)
- Joel Sjöblom (Turku)
- Elio Nushi (Turku) •